Clinical Trial Update: Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating multi-virus cytotoxic T lymphocytes engineered with CD19 chimeric receptors for CD19-positive malignancies after stem cell transplant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Multi-virus CTLs expressing CD19 Chimeric Receptors (CD19 CAR T cells)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Status: ACTIVE_NOT_RECRUITING